Cytek Biosciences Stock – A Play on Flow Cytometry

July 28. 2021. 4 mins read

Physicist Richard Feynman’s famous talk “There’s Plenty of Room at the Bottom” proposed that mankind would eventually get around to creating things at a cellular level, and it looks like we’ve started down that path. The single-cell revolution is here, with about a dozen life sciences companies offering technology platforms for working with cells. Today, we’re going to look at another firm doing cool things at a cellular level – Cytek Biosciences (CTKB).

About Cytek Biosciences Stock

Click for company website

We previously discussed the “single-cell revolution” and looked at a handful of companies offering pick-and-shovel platforms for manipulating and analyzing cells. For whatever reason, Cytek Biosciences wasn’t on that list, perhaps because their underlying technology has been around since the 1970s. The company dabbles in something called flow cytometry, a technique for analyzing the physical and chemical characteristics of a population of cells. Using lasers and fluorescent tags, cells can be studied by researchers in fields such as molecular biology, pathology, immunology, virology,

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.